Regencell Bioscience Holdings Limited RGC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 269.46% | 167.33% | 83.20% | 26.21% | -25.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 210.99% | 130.73% | 62.01% | 19.29% | -20.41% |
| Operating Income | -210.99% | -130.73% | -62.01% | -19.29% | 20.41% |
| Income Before Tax | -226.49% | -146.23% | -74.86% | -26.67% | 17.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -226.49% | -146.23% | -74.86% | -26.67% | 17.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -226.49% | -144.37% | -72.39% | -26.72% | 16.68% |
| EBIT | -210.99% | -130.73% | -62.01% | -19.29% | 20.41% |
| EBITDA | -215.36% | -137.12% | -68.19% | -24.49% | 16.85% |
| EPS Basic | -230.56% | -143.59% | -69.05% | -24.42% | 18.18% |
| Normalized Basic EPS | -208.33% | -126.42% | -58.62% | -52.17% | -41.18% |
| EPS Diluted | -230.56% | -143.59% | -69.05% | -24.42% | 18.18% |
| Normalized Diluted EPS | -208.33% | -126.42% | -58.62% | -52.17% | -41.18% |
| Average Basic Shares Outstanding | 0.02% | 0.01% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.02% | 0.01% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |